Search

Your search keyword '"Eshel, Rinat"' showing total 24 results
Start Over Author "Eshel, Rinat"
Sorry, I don't understand your search. ×
24 results on '"Eshel, Rinat"'

1. Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study

Author

Ram, Ron, Hagin, David, Kikozashvilli, Nino, Freund, Tal, Amit, Odelia, Bar-On, Yael, Beyar-Katz, Ofrat, Shefer, Gabi, Moshiashvili, Miguel Morales, Karni, Chen, Gold, Ronit, Kay, Sigi, Glait-Santar, Chen, Eshel, Rinat, Perry, Chava, Avivi, Irit, Apel, Arie, Benyamini, Noam, Shasha, David, and Ben-Ami, Ronen

Published
2021
Full Text
View/download PDF

8. Significant correlation between peripheral blood CD34+ cell count in children prior to aphaeresis and CD34+ cell yield following aphaeresis: A single-center experience

Author

Rosenfeld-Keidar, Hila, primary, Eshel, Rinat, additional, Pinhasov, Aviva, additional, Bitan, Menachem, additional, Edelman, Sabina, additional, Broitman, Marcela, additional, Dvir, Rina, additional, Sadot, Efraim, additional, Levin, Dror, additional, Manisterski, Michal, additional, Berger-Achituv, Sivan, additional, and Elhasid, Ronit, additional

Published
2018
Full Text
View/download PDF

9. Toxicity and efficacy of autologous hematopoietic cell transplantation in elderly patients with aggressive lymphoma: a historical prospective study.

Author

Davidov, Marina, Perry, Chava, Herishanu, Yair, Sarid, Nadav, Rom, Esti, Amit, Odelia, Eshel, Rinat, Naparstek, Ella, Avivi, Irit, and Ram, Ron

Subjects
HEMATOPOIETIC stem cell transplantation, LYMPHOMAS, OLDER patients, MUCOSITIS, LUNG diseases, LYMPHOMA treatment, AGE distribution, AUTOGRAFTS, CANCER relapse, CANCER invasiveness, HOSPITAL care, LONGITUDINAL method, TREATMENT effectiveness
Abstract

High-dose therapy followed by autologous hematopoietic cell transplantation (HCT) prolongs overall survival in patients under 65 years old with relapsed aggressive lymphoma. We aimed to explore the toxicity and efficacy of HCT in patients over 65 years with aggressive lymphoma compared with younger patients. We compared the transplantation outcomes between patients ≥ 65 years (n = 58) and 55-64 years (n = 44) with chemosensitive aggressive lymphoma (DLBCL, MCL and TCL) that underwent HCT between 1999 and 2016 in the Tel-Aviv Medical Center. The median age was 68 (range, 65-74) and 61 (range, 55-64) years, respectively. There were no differences in the incidences of grade 3-4 mucositis, documented infections and pulmonary complications between the two groups. There was no difference in the incidences of secondary malignancies, relapse (p = .26), non-relapse mortality, (p = .77) and overall survival (p = .53). Multivariate analysis revealed that smoking was a risk factor for non-relapse mortality, while partial remission and > 2 lines of treatment prior HCT were associated with higher risk for relapse. Psycho-socioeconomic score was associated with prolonged hospitalization after HCT and recurrent hospitalizations. We conclude that patients ≥ 65 years old with aggressive lymphoma, compared to younger counterparts, have similar transplantation outcome. Improving habits and psychosocial factors may further improve outcomes in these patients. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

11. Unexpected detection of monoclonal B‐cell lymphocytosis in a HLA‐matched sibling donor on the day of allogeneic stem cell transplantation for a patient with chronic lymphocytic leukaemia: clinical outcome

Author

Herishanu, Yair, primary, Eshel, Rinat, additional, Kay, Sigi, additional, Rothman, Rachel, additional, Njuguna, Ndegwa, additional, Perry, Chava, additional, Shpringer, Meirav, additional, Wiestner, Adrian, additional, Polliack, Aaron, additional, and Naparstek, Elizabeth, additional

Published
2010
Full Text
View/download PDF

20. Expression of Ly-6, a marker for highly malignant murine tumor cells, is regulated by growth conditions and stress

Author

Treister, Alexandra, primary, Sagi-Assif, Orit, additional, Meer, Michal, additional, I. Smorodinsky, Nechama, additional, Anavi, Romema, additional, Golan, Itshak, additional, Meshel, Tzipora, additional, Kahana, Orlie, additional, Eshel, Rinat, additional, Katz, Ben-Zion, additional, Shevach, Ethan, additional, and P. Witz, Isaac, additional

Published
1998
Full Text
View/download PDF

24. Acute myeloid leukemia with 11q23/ MLL rearrangement after ' FCR' regimen for chronic lymphocytic leukemia.

Author

Sarid, Nadav, Eshel, Rinat, Rothman, Rachel, Shpringer, Meirav, Perry, Chava, Solar, Irit, Dezorella, Nili, Gepstein, Lili, Canaani, Jonathan, Naparstek, Elizabeth, Polliack, Aaron, and Herishanu, Yair

Subjects
*LETTERS to the editor, *ACUTE myeloid leukemia, *FLUDARABINE
Abstract

A letter to the editor is presented regarding the case of rearrangement of 11q23/mixed-lineage leukemia (MLL) in acute myeloid leukemia (AML) after the application of fludarabine, cyclophosphamide, and rituximab (FCR).

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results